Table 1.
Patient demographic and clinical characteristics
| Dose of thymoglobulin | ||||
|---|---|---|---|---|
| All patients | 4.5 mg/kg | 7.5 mg/kg | p-value | |
| N (%) | N (%) | N (%) | ||
| Number of patients | 20 | 15 | 5 | |
| Sex | 0.6169 | |||
| Female | 9 (45.0) | 6 (40.0) | 3 (60.0) | |
| Male | 11 (55.0) | 9 (60.0) | 2 (40.0) | |
| Age at transplant (years) | 0.6674 | |||
| Median (range) | 60 (40–75) | 60 (40–75) | 62 (50–67) | |
| Diagnosis | 0.5395 | |||
| AML | 17 (85.0) | 12 (80.0) | 5 (100.0) | |
| MDS | 3 (15.0) | 3 (20.0) | 0 (0.0) | |
| CR at transplant | 0.3034 | |||
| No | 10 (50.0) | 9 (60.0) | 1 (20.0) | |
| Yes | 10 (50.0) | 6 (40.0) | 4 (80.0) | |
| Stem cell source | 0.1089 | |||
| Peripheral blood | 12 (60.0) | 11 (73.3) | 1 (20.0) | |
| Bone marrow | 8 (40.0) | 4 (26.7) | 4 (80.0) | |
| TNC (×108/kg) | 0.1227 | |||
| Median (range) | 9 (2.6–17.7) | 10.8 (3.1–17.7) | 4.4 (2.6–9.8) | |
| CD34+(×106/kg) | 0.467 | |||
| Median (range) | 5.6 (1.3–36.4) | 5.9 (1.3–36.4) | 5.3 (1.8–7.3) | |
| Acute GVHD | 0.3034 | |||
| No | 10 (50.0) | 6 (40.0) | 4 (80.0) | |
| Yes | 10 (50.0) | 9 (60.0) | 1 (20.0) | |
| Acute GVHD grade | 0.5240 | |||
| 0 | 10 (50.0) | 6 (40.0) | 4 (80.0) | |
| I | 6 (30.0) | 5 (33.3) | 1 (20.0) | |
| II | 2 (10.0) | 2 (13.3) | 0 (0.0) | |
| III | 2 (10.0) | 2 (13.3) | 0 (0.0) | |
| Neutrophilengraftment | 0.9999 | |||
| No | 1 (5.0) | 1 (6.7) | 0 (0.0) | |
| Yes | 19 (95.0) | 14 (93.3) | 5 (100.0) | |
| Platelet engraftment | 0.9999 | |||
| No | 4 (20.0) | 3 (20.0) | 1 (20.0) | |
| Yes | 16 (80.0) | 12 (80.0) | 4 (80.0) | |
| Limited chronic GVHD | 0.9999 | |||
| No | 8 (61.5) | 7 (63.6) | 1 (50.0) | |
| Yes | 5 (38.5) | 4 (36.4) | 1 (50.0) | |
| Extensive chronic GVHD | 0.9999 | |||
| No | 10 (76.9) | 8 (72.7) | 2 (100.0) | |
| Yes | 3 (23.1) | 3 (27.3) | 0 (0.0) | |
AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; CR, complete remission; TNC, total nucleated cells; GVHD, graft-versus-host disease